These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy]. Sauvètre G; Grange S; Froissart A; Veyradier A; Coppo P; Benhamou Y Rev Med Interne; 2015 May; 36(5):328-38. PubMed ID: 25547956 [TBL] [Abstract][Full Text] [Related]
5. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Verhave JC; Wetzels JF; van de Kar NC Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv131-41. PubMed ID: 25165180 [TBL] [Abstract][Full Text] [Related]
7. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. Darwin A; Malpica L; Dhanoa J; Hashmi H BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637496 [TBL] [Abstract][Full Text] [Related]
8. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512 [TBL] [Abstract][Full Text] [Related]
9. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670 [TBL] [Abstract][Full Text] [Related]
10. Complement Activation and Thrombotic Microangiopathies. Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864 [TBL] [Abstract][Full Text] [Related]
11. Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Freyer CW; Bange EM; Skuli S; Hsu M; Lin J; Cuker A; Cohen AD; Garfall A Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e845-e849. PubMed ID: 34366267 [No Abstract] [Full Text] [Related]
12. Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes. Joseph A; Rafat C; Zafrani L; Mariani-Kurkdjian P; Veyradier A; Hertig A; Rondeau E; Mariotte E; Azoulay E Crit Care Med; 2018 Sep; 46(9):e904-e911. PubMed ID: 29979220 [TBL] [Abstract][Full Text] [Related]
13. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Bhutani D; Assal A; Mapara MY; Prinzing S; Lentzsch S Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):e155-e157. PubMed ID: 32098724 [No Abstract] [Full Text] [Related]
14. Atypical hemolytic uremic syndrome: a case report. Basnayake BMDB; Wazil AWM; Nanayakkara N; Samarakoon SMDK; Senavirathne EMSK; Thangarajah BUEWDR; Karunasena N; Mahanama RMBSS J Med Case Rep; 2020 Jan; 14(1):11. PubMed ID: 31928535 [TBL] [Abstract][Full Text] [Related]
15. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement. Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078 [TBL] [Abstract][Full Text] [Related]
16. [Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report]. Reis S; Ramos D; Cordinhã C; Gomes C Acta Med Port; 2019 Oct; 32(10):673-675. PubMed ID: 31625881 [TBL] [Abstract][Full Text] [Related]
17. Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next? Fakhouri F; Frémeaux-Bacchi V Nat Rev Nephrol; 2013 Sep; 9(9):495-6. PubMed ID: 23917793 [No Abstract] [Full Text] [Related]
18. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches]. Kistler AD Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733 [TBL] [Abstract][Full Text] [Related]
19. Where are we with haemolytic uremic syndrome? Cavero T; Alonso M Med Clin (Barc); 2018 Oct; 151(8):329-335. PubMed ID: 29699703 [TBL] [Abstract][Full Text] [Related]
20. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review]. Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]